Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Transcatheter aortic valve implantation with the self-expanding Portico valve system in an all-comers population: procedural and clinical outcomes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Mechanical circulatory support for decompensated heart failure: the last remaining indication for intra-aortic balloon pump?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Transcatheter mitral valve repair: a step back from the edge

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The invisible army of women in interventional cardiology: EAPCI Women mission to make them visible

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mortality and morbidity of major congenital heart disease related to general prenatal screening for malformations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-Term Risk of Infective Endocarditis After Transcatheter Aortic Valve Replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-Term Outcomes of Partial Oral Treatment of Endocarditis

    Publikation: Bidrag til tidsskriftLetterForskning

Vis graf over relationer

AIMS: Transcatheter aortic valve implantation (TAVI) is an established therapy for patients with severe aortic stenosis (AS). The aim of this study was to evaluate the newer-generation Portico TAVI system in an all-comers population.

METHODS AND RESULTS: This single-centre study included 216 patients with severe AS (Society of Thoracic Surgeons [STS] score 4.3±3.0%). The Portico valve was implanted using the transfemoral (91.2%), transsubclavian (5.6%) and transcaval (3.2%) access. Device success was achieved in 94.4% of cases. At 30 days, mortality and stroke rates were 2.3% and 0.5%, respectively. Early safety was achieved in 91.7% of cases. More-than-mild paravalvular leak (PVL), as assessed by echocardiogram, was observed in 3.4% of the patients, with rates of 4.9% and 1.9% in the first and second half of the cohort, respectively. A permanent pacemaker was implanted in 15.8% of those without prior pacemaker, with a rate of 11.1% in the second half of the cohort. At one year, incidence rates for all-cause mortality and stroke were 12.3% and 2.3%, respectively. In the low-risk group (STS <4%; n=128), Kaplan-Meier estimates at 30 days and one year were 0% and 7.5% for all-cause mortality and 0.8% and 2.2% for stroke, respectively. Haemodynamic improvements persisted over time with a mean transvalvular gradient of 7.0±3.0 mmHg at one-year follow-up.

CONCLUSIONS: The Portico TAVI system was safe to implant and achieved a high device success rate. With learning curve effects, the device achieves lower rates of PVL and pacemaker implantation and provides adequate clinical and haemodynamic outcomes up to one year.

OriginalsprogEngelsk
TidsskriftEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Vol/bind14
Udgave nummer6
Sider (fra-til)621-628
Antal sider8
ISSN1774-024X
DOI
StatusUdgivet - 20 aug. 2018

ID: 56380079